On October 20, 2023, a novel extended-release siRNA targeting KRASG12D/V (G12D/V) mutations (Loder) in combination with standard chemotherapy was reported at the ESMO Congress.

On 23 Oct 2023, the results from a phase II trial of endostar in patients with locally advanced squamous cell carcinoma of esophagus were reported at the ESMO Congress.

On October 20, 2023, “Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in older patients (pts) ”was reported at the ESMO Congress.

[177Lu]Lu-PSMA-617 extends survival in mCRPC patients previously treated with ARPI, but its impact without prior taxane treatment was unclear until revealed at the ESCO Congress.

The latest research trial study of CBP-501 for the treatment of metastatic PDAC reported at the ESMO Congress exhibits promising therapeutic benefits.

On October 20, 2023, the first-in-human trial of BDC-1001 in advanced HER2-positive solid tumors was reported at the ESMO Congress.